Tags

Type your tag names separated by a space and hit enter

Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia.
World J Psychiatry. 2020 Apr 19; 10(4):29-33.WJ

Abstract

Behavioral and psychological symptoms including agitation are common in dementia, and are associated with decreased quality of life, increased risk of institutionalization, and greater patient and caregiver distress. Pharmacological agents used for management of behavioral and psychological symptoms of dementia are limited by their tolerability, prompting a need for identifying efficacious and safe pharmacological treatments for managing agitation in dementia. The combination of dextromethorphan and quinidine sulfate is approved for pseudobulbar affect, and may be effective in managing agitation in dementia. A review of literature found only one randomized controlled trial that evaluated the use of dextromethorphan-quinidine for the management of agitation in dementia when compared to placebo. Data from this trial demonstrated that dextromethorphan-quinidine decreased agitation in dementia, and was well tolerated. Although promising, further research is needed before dextromethorphan-quinidine combination can be accepted as a standard treatment for agitation in dementia.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH 44106, United States.Department of Psychiatry and Behavioral Sciences, Northwell Health-Staten Island University Hospital, Staten Island, NY 10306, United States.Department of Psychiatry, Einstein Medical Center, Philadelphia, PA 19141, United States.Diamond Healthcare, Richmond, VA 23219, United States.

Pub Type(s)

Editorial

Language

eng

PubMed ID

32399396

Citation

Tampi, Rajesh R., et al. "Evidence for Using Dextromethorphan-quinidine for the Treatment of Agitation in Dementia." World Journal of Psychiatry, vol. 10, no. 4, 2020, pp. 29-33.
Tampi RR, Joshi P, Marpuri P, et al. Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia. World J Psychiatry. 2020;10(4):29-33.
Tampi, R. R., Joshi, P., Marpuri, P., & Tampi, D. J. (2020). Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia. World Journal of Psychiatry, 10(4), 29-33. https://doi.org/10.5498/wjp.v10.i4.29
Tampi RR, et al. Evidence for Using Dextromethorphan-quinidine for the Treatment of Agitation in Dementia. World J Psychiatry. 2020 Apr 19;10(4):29-33. PubMed PMID: 32399396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia. AU - Tampi,Rajesh R, AU - Joshi,Pallavi, AU - Marpuri,Padmapriya, AU - Tampi,Deena J, Y1 - 2020/04/19/ PY - 2020/02/08/received PY - 2020/03/03/revised PY - 2020/03/22/accepted PY - 2020/5/14/entrez PY - 2020/5/14/pubmed PY - 2020/5/14/medline KW - Agitation KW - Behavioral and psychological symptoms of dementia KW - Dementia KW - Dextromethorphan KW - Quinidine SP - 29 EP - 33 JF - World journal of psychiatry JO - World J Psychiatry VL - 10 IS - 4 N2 - Behavioral and psychological symptoms including agitation are common in dementia, and are associated with decreased quality of life, increased risk of institutionalization, and greater patient and caregiver distress. Pharmacological agents used for management of behavioral and psychological symptoms of dementia are limited by their tolerability, prompting a need for identifying efficacious and safe pharmacological treatments for managing agitation in dementia. The combination of dextromethorphan and quinidine sulfate is approved for pseudobulbar affect, and may be effective in managing agitation in dementia. A review of literature found only one randomized controlled trial that evaluated the use of dextromethorphan-quinidine for the management of agitation in dementia when compared to placebo. Data from this trial demonstrated that dextromethorphan-quinidine decreased agitation in dementia, and was well tolerated. Although promising, further research is needed before dextromethorphan-quinidine combination can be accepted as a standard treatment for agitation in dementia. SN - 2220-3206 UR - https://www.unboundmedicine.com/medline/citation/32399396/Evidence_for_using_dextromethorphan-quinidine_for_the_treatment_of_agitation_in_dementia L2 - http://www.wjgnet.com/2220-3206/full/v10/i4/29.htm DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.